Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.

ABSTRACT:

Objective

This study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).

Methods

Fifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunological response, renal function and adverse events were assessed throughout the follow-up period between patients receiving obinutuzumab as initial therapy and alternative therapy.

Results

The study included 40 patients receiving obinutuzumab as an alternative therapy, and 15 patients receiving it as an initial therapy. During a follow up of 13.0(10.0, 18.0) months after obinutuzumab treatment, 23/25(92.0%) patients achieved immunological remission. 46/55(83.6%) patients ach

SUBMITTER: Cheng X 

PROVIDER: S-EPMC12408494 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature